CarGurus, the leading automotive shopping platform in the U.S., will announce its financial results for the third quarter ending September 30, 2026, after market close on November 5, 2026. The company will host a conference call and live webcast at 5:00 p.m. Eastern Time to discuss the results and business outlook. Investors can access the call via phone or online, with a replay available until November 19. This update is important as it provides insights into CarGurus' performance and future prospects in the competitive automotive marketplace.
CarGurus' upcoming Q3 2026 financial results provide context for readers interested in the automotive and consumer cyclical sectors. For readers following Consumer Cyclical stocks, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: Of 134 priced US Consumer Cyclical stocks, 53 rose and 80 fell. Notable movers include Wayfair Inc (W) at USD 111.80 with a 1-day change of +4.21%, Tapestry, Inc. (TPR) at USD 119.73 with a 1-day change of +4.09% and 100% sell order activity, and Figs Inc (FIGS) at USD 19.39 with a 1-day change of +4.08%.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
